Abstract
Relapses or flares of systemic lupus erythematosus (SLE) are frequent and observed in 27–66% of patients. SLE flares are defined as an increase in disease activity, in general, requiring alternative treatment or intensification of therapy. A renal flare is indicated by an increase in proteinuria and/or serum creatinine concentration, abnormal urine sediment or a reduction in creatinine clearance rate as a result of active disease. The morbidity associated with renal flares is derived from both the kidney damage due to lupus nephritis and treatment-related toxic effects. Current induction treatment protocols achieve remission in the majority of patients with lupus nephritis; however, few studies focus on treatment interventions for renal flares in these patients. The available data, however, suggest that remission can be induced again in a substantial percentage of patients experiencing a lupus nephritis flare. Lupus nephritis flares are independently associated with an increased risk of deterioration in renal function; prevention of renal flares might, therefore, also decrease long-term morbidity and mortality. Appropriate immunosuppressive maintenance therapy might lead to a decrease in the occurrence of renal and extrarenal flares in patients with SLE, and monitoring for the early detection and treatment of renal flares could improve their outcomes.
Key Points
-
Renal flares are associated with impaired renal prognosis and increased cumulative exposure of patients to drug toxic effects
-
Proteinuric flare is defined as persistently increased proteinuria (>0.5–1.0 g daily) after a complete response, or doubling of proteinuria (to >1.0 g daily) after a partial response
-
A nephritic flare is defined as an increase or recurrence of urinary sediment with or without increased proteinuria, and is usually associated with a decline in renal function
-
Reappearance of urinary casts and increased titres of antibodies to double-stranded DNA can predict renal flares
-
Whether monitoring of novel urinary or serum biomarkers can be used to predict lupus nephritis flares remains to be proven in prospective clinical trials
-
Prolonging the duration of maintenance therapy and careful clinical monitoring seem to decrease the incidence and severity of renal flares
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Appel, G. B. & Jayne, D. Lupus nephritis in Comprehensive Clinical Nephrology (eds Floege, J., Johnson, R. J. & Feehaly, J.) 308–321 (Saunders Elsevier, St. Louis, 2010).
Moroni, G., Quaglini, S., Maccario, M., Banfi, G. & Ponticelli, C. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 50, 2047–2053 (1996).
Moroni, G. et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol. Dial. Transplant. 22, 2531–2539 (2007).
Mosca, M. et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 61, 1502–1509 (2002).
Contreras, G. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971–980 (2004).
Moroni, G. et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin. J. Am. Soc. Nephrol. 1, 925–932 (2006).
Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886–1895 (2011).
Houssiau, F. A. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69, 2083–2089, (2010).
Gordon, C. et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 18, 257–263 (2009).
Fiehn, C. et al. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann. Rheum. Dis. 62, 435–439 (2003).
Houssiau, F. A. et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50, 3934–3940 (2004).
Brunner, H. I. et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 54, 2577–2584 (2006).
Brunner, H. I. et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 64, 2687–2697 (2012).
Rovin, B. H., Song, H., Birmingham, D. J., Hebert, L. A., Yu, C. Y. & Nagaraja, H. N. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 16, 467–473 (2005).
Zhang, X. et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 74, 799–807 (2008).
Schwartz, N. et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res. Ther. 11, R143 (2009).
Satoskar, A. A. et al. Discrepancies in glomerular and tubulointerstitial/vascular immune complex IgG subclasses in lupus nephritis. Lupus 20, 1396–1403 (2011).
Fine, D. M. et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int. 76, 1284–1288 (2009).
Birmingham, D. J. et al. Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int. 72, 865–870 (2007).
Hebert, L. A. et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin. Pract. 113, c177–c182 (2009).
Kraft, S. W., Schwartz, M. M., Korbet, S. M. & Lewis, E. J. Glomerular podocytopathy in patients with systemic lupus erythematosus. J. Am. Soc. Nephrol. 16, 175–179 (2005).
Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15, 241–250 (2004).
Donadio, J. V. Jr, Holley, K. E., Ferguson, R. H. & Ilstrup, D. M. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N. Engl. J. Med. 299, 1151–1155 (1978).
Boumpas, D. T. et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340, 741–745 (1992).
Ciruelo, E., de la, Cruz, J., Lopez, I. & Gomez-Reino, J. J. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum. 39, 2028–2034 (1996).
Gourley, M. F. et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 125, 549–557 (1996).
Ioannidis, J. P. & Moutsopoulos, H. M. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 57, 258–264 (2000).
Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343, 1156–1162 (2000).
Illei, G. G. et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 46, 995–1002 (2002).
Mok, C. C., Ho, C. T., Chan, K. W., Lau, C. S. & Wong, R. W. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. 46, 1003–1013 (2002).
Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121–2131 (2002).
El Hachmi, M., Jadoul, M., Lefebvre, C., Depresseux, G. & Houssiau, F. A. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 12, 692–696 (2003).
Chan, T. M., Tse, K. C., Tang, C. S., Mok, M. Y. & Li, F. K. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 16, 1076–1084 (2005).
Moroni, G. et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol. Dial. Transplant. 21, 1541–1548 (2006).
Mok, C. C., Ying, K. Y., Yim, C. W., Ng, W. L. & Wong, W. S. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus 18, 1091–1095 (2009).
Grootscholten, C. & Berden, J. H. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol. Dial. Transplant. 21, 1465–1469 (2006).
Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219–2228 (2005).
Contreras, G., Tozman, E., Nahar, N. & Metz, D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14 (Suppl. 1), s33–s38 (2005).
Sinclair, A. et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16, 972–980 (2007).
Chagnac, A. et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J. Clin. Invest. 84, 922–930 (1989).
Valeri, A. et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin. Nephrol. 42, 71–78 (1994).
Hebert, L. A., Dillon, J. J., Middendorf, D. F., Lewis, E. J. & Peter, J. B. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am. J. Kidney Dis. 26, 432–438 (1995).
Marto, N., Bertolaccini, M. L., Calabuig, E., Hughes, G. R. & Khamashta, M. A. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 444–448 (2005).
Matrat, A. et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 20, 28–34 (2011).
Mak, A., Cheung, B. M., Mok, C. C., Leung, R. & Lau, C. S. Adrenomedullin—a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus. Rheumatology (Oxford) 45, 1266–1272 (2006).
Oates, J. C., Shaftman, S. R., Self, S. E. & Gilkeson, G. S. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 58, 263–272 (2008).
Mosley, K. et al. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 45, 1497–1504 (2006).
Chan, R. W. et al. Expression of T-bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients predicts disease flare. Rheumatology (Oxford) 46, 44–48 (2007).
Pitashny, M. et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum. 56, 1894–1903 (2007).
Xuejing, Z. et al. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J. Biomed. Biotechnol. http://dx.doi.org/10.1155/2012/359647 (2012).
Schwartz, N. et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res. Ther. 11, R143 (2009).
Schwartz, N. et al. Urinary TWEAK and the activity of lupus nephritis. J. Autoimmun. 27, 242–250 (2006).
Feng, X. et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2951–2962 (2006).
Oates, J. C. et al. Prediction of urinary protein markers in lupus nephritis. Kidney Int. 68, 2588–2592 (2005).
Varghese, S. A. et al. Urine biomarkers predict the cause of glomerular disease. J. Am. Soc. Nephrol. 18, 913–922 (2007).
Suzuki, M. et al. Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr. Nephrol. 22, 2047–2057 (2007).
Rubinstein, T. et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 49, 960–971 (2010).
West, C. D. Relative value of serum C3 and C4 levels in predicting relapse in systemic lupus erythematosus. Am. J. Kidney Dis. 18, 686–688 (1991).
ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C. & Kallenberg C. G. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 33, 634–643 (1990).
Akhter, E., Burlingame, R. W., Seaman, A. L., Magder, L. & Petri, M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 20, 1267–1274 (2011).
Bootsma, H. et al. Prevention of relapses in systemic lupus erythematosus. Lancet 345, 1595–1599 (1995).
Moroni, G. et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am. J. Kidney Dis. 34, 530–539 (1999).
Bertsias, G. & Boumpas, D. T. Update on the management of lupus nephritis: let the treatment fit the patient. Nat. Clin. Pract. Rheumatol. 4, 464–472 (2008).
Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121–2131 (2002).
Alsuwaida, A. Successful management of systemic lupus erythematosus nephritis flare-up during pregnancy with tacrolimus. Mod. Rheumatol. 21, 73–75 (2011).
Szeto, C. C. et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 47, 1678–1681 (2008).
Melander, C. et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin. J. Am. Soc. Nephrol. 4, 579–587 (2009).
Moroni, G. et al. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Ann. Rheum. Dis. 71, 1751–1752 (2012).
Boletis, J. N. et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol. Dial. Transplant. 24, 2157–2160 (2009).
Houssiau, F. A. & Ginzler E. M. Current treatment of lupus nephritis. Lupus 17, 426–430 (2008).
Austin, H. A. & Balow J. E. Natural history and treatment of lupus nephritis. Semin. Nephrol. 19, 2–11 (1999).
Chen, W. et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 21, 944–952 (2012).
Uchino, A. et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin. Exp. Rheumatol. 28, 6–12 (2010).
Camous, L. et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am. J. Kidney Dis. 52, 346–352 (2008).
Nguyen, T., Vacek, P. M., O'Neill, P., Colletti, R. B. & Finette, B. A. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res. 69, 7004–7012 (2009).
Anderka, M. T., Lin, A. E., Abuelo, D. N., Mitchell, A. A. & Rasmussen S. A. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am. J. Med. Genet. 149A, 1241–1248 (2009).
Hill, G. S. et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 59, 304–316 (2001).
Hill, G. S. et al. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int. 61, 2176–2186 (2002).
Baranowska-Daca, E. et al. Nonlupus nephritides in patients with systemic lupus erythematosus: a comprehensive clinicopathologic study and review of the literature. Hum. Pathol. 32, 1125–1135 (2001).
Daugas, E. et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J. Am. Soc. Nephrol. 13, 42–52 (2002).
Tektonidou, M. G., Sotsiou, F., Nakopoulou, L., Vlachoyiannopoulos, P. G. & Moutsopoulos H. M. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 50, 2569–2579 (2004).
Cheunsuchon, B., Rungkaew, P., Chawanasuntorapoj, R., Pattaragarn, A. & Parichatikanond, P. Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies. Nephrology (Carlton) 12, 474–480 (2007).
Bajaj, S. et al. Serial renal biopsy in systemic lupus erythematosus. J. Rheumatol. 27, 2822–2826 (2000).
Gunnarsson, I. et al. Repeated renal biopsy in proliferative lupus nephritis—predictive role of serum C1q and albuminuria. J. Rheumatol. 29, 693–699 (2002).
Tam, L. S., Li, E. K., Lai, F. M., Chan, Y. K. & Szeto, C. C. Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. Lupus 12, 665–671 (2003).
Appel, G. B., Cohen, D. J., Pirani, C. L., Meltzer, J. I. & Estes, D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am. J. Med. 83, 877–885 (1987).
Author information
Authors and Affiliations
Contributions
B. Sprangers and G. Appel researched the data for the article. B. Sprangers wrote the article. B. Sprangers, G. Appel and M. Monahan provided substantial contributions to discussion of the content and to review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
G. B. Appel has consulted for and received research grants from Aspreva–Vifor, Genentech, La Jolla Pharmaceuticals and Roche. He has also served on the Bristol–Myers Squibb adjudication committee for lupus nephritis. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Sprangers, B., Monahan, M. & Appel, G. Diagnosis and treatment of lupus nephritis flares—an update. Nat Rev Nephrol 8, 709–717 (2012). https://doi.org/10.1038/nrneph.2012.220
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.220
This article is cited by
-
Incorporating knowledge of disease-defining hub genes and regulatory network into a machine learning-based model for predicting treatment response in lupus nephritis after the first renal flare
Journal of Translational Medicine (2023)
-
B1-cell-produced anti-phosphatidylserine antibodies contribute to lupus nephritis development via TLR-mediated Syk activation
Cellular & Molecular Immunology (2023)
-
Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study
Rheumatology and Therapy (2023)
-
Omics-based integrated analysis identified IKZF2 as a biomarker associated with lupus nephritis
Scientific Reports (2022)
-
The association of 5-year therapeutic responsiveness with long-term renal outcome in IgA nephropathy
Clinical and Experimental Nephrology (2022)